Alzumab-L Injection

Alzumab-L Injection is given by intravenous infusion by a doctor or a nurse in a hospital or clinical setting. It is infused slowly over several hours. It is important to attend every scheduled dose and monitoring appointment since treatment response and safety are closely observed. The treatment schedule should be followed exactly as directed by the doctor.

Some people may experience infusion-related reactions during or after receiving Alzumab-L Injection, such as chills, fever, rash, cough, breathing difficulty, flushing, headache, or changes in blood pressure. These are more common during the first infusion and usually improve with slower administration and appropriate management.

Alzumab-L Injection should not be used in people who have had a severe allergic reaction to itolizumab or any ingredients in this product. Before starting treatment, patients must be screened for tuberculosis, and treatment should be used with caution in those with a history of recurrent infections or immunocompromised status. Vaccines should generally be avoided during therapy. Use during pregnancy or breastfeeding is not recommended due to insufficient safety data.

• Treatment of moderate to severe plaque Psoriasis
• Treatment of Acute Respiratory Distress Syndrome

• Keep a watch on any sign or symptom of new infection during and after the treatment with Alzumab-L Injection. Report immediately to your doctor.
• Inform your doctor if you have any kidney or liver disease.
• Inform your doctor if you are pregnant or breastfeeding.
• Let your doctor know if you have any history of severe allergies.